Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Depreciation and Depletion (2021 - 2022)

Rani Therapeutics Holdings (RANI) has 2 years of Depreciation and Depletion data on record, last reported at $126000.0 in Q4 2022.

  • For Q4 2022, Depreciation and Depletion rose 8.62% year-over-year to $126000.0; the TTM value through Dec 2022 reached $500000.0, changed 0.0%, while the annual FY2024 figure was $1.0 million, 25.0% up from the prior year.
  • Depreciation and Depletion reached $126000.0 in Q4 2022 per RANI's latest filing, down from $141000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $141000.0 in Q3 2022 and bottomed at $111000.0 in Q1 2022.